Tcelna (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tcelna" in English language version.

refsWebsite

Global rank English rank

4^th place

2^nd place

3,011^th place

2,709^th place

1^st place

low place

doi.org

Loftus B, Newsom B, Montgomery M, Von Gynz-Rekowski K, Riser M, Inman S, Garces P, Rill D, Zhang J, Williams JC (2009). "Autologous attenuated T cell vaccine (Tcelna) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies". Clinical Immunology. 131 (2): 202–15. doi:10.1016/j.clim.2009.01.005. PMID 19230777.
Shirani, Afsaneh; Okuda, Darin T.; Stüve, Olaf (4 January 2016). "Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis". Neurotherapeutics. 13 (1): 58–69. doi:10.1007/s13311-015-0409-z. PMC 4720678. PMID 26729332.

"Opexa Therapeutics Announces Completion Of Mid Study Descriptive Analysis On Phase IIb Trial Of Tcelna" [1] Archived 2009-01-03 at the Wayback Machine

Loftus B, Newsom B, Montgomery M, Von Gynz-Rekowski K, Riser M, Inman S, Garces P, Rill D, Zhang J, Williams JC (2009). "Autologous attenuated T cell vaccine (Tcelna) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies". Clinical Immunology. 131 (2): 202–15. doi:10.1016/j.clim.2009.01.005. PMID 19230777.
Shirani, Afsaneh; Okuda, Darin T.; Stüve, Olaf (4 January 2016). "Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis". Neurotherapeutics. 13 (1): 58–69. doi:10.1007/s13311-015-0409-z. PMC 4720678. PMID 26729332.

"Opexa Therapeutics Announces Completion Of Mid Study Descriptive Analysis On Phase IIb Trial Of Tcelna" [1] Archived 2009-01-03 at the Wayback Machine